Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Xin Wang

Harvard Medical School, USA.

Title: Therapeutic neuroprotective agents for ALS

Biography

Biography: Xin Wang

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal and rare chronic neurodegenerative disease. Multiple mechanisms proposed as responsible for ALS pathogenesis include mitochondrial dysfunction, apoptosis, oxidative stress, inflammation, glutamate excitotoxicity, and protein degradation. Because riluzole, the only Food and Drug Administration (FDA)-approved treatment, prolongs the ALS patient’s life by only 3 months, new therapeutic treatments that may delay disease onset, slow progression, prolong survival, and ultimately reduce the burden of disease are urgently needed. The impact of various small pharmacological compounds targeting the proposed pathogenic mechanisms of ALS will be summarized. Furthermore, melatonin, an agonist of melatonin receptors, delays disease onset, extends lifespan, and slows progression of mSOD1G93A ALS transgenic mice will be discussed.